Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Tempus AI, Inc.

Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus to Report Third Quarter 2024 Financial Results on November 4
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces Collaboration With JW Pharmaceutical to Apply Real-World Data and Biological Modeling to Enhance Early Research and Development
From Tempus AI, Inc.
Via Business Wire
Tempus to Report Third Quarter 2024 Financial Results on November 7
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024
From Tempus AI, Inc.
Via Business Wire
Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces Real World Data Collaboration with BioNTech
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
NPJ Precision Oncology Publishes Tempus Study on Validation of its HLA-LOH Investigational Assay
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Reports Second Quarter 2024 Results
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces Expanded Data and Sequencing Collaboration with Remix Therapeutics
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus to Report Second Quarter 2024 Financial Results on August 6
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Expands Immuno-Oncology Portfolio with Launch of AI-enabled, Multimodal Immune Profile Algorithmic Tests
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Surpasses 500 Research Publications
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
American Medical Association Grants PLA Code to Tempus Algorithmic Test, PurISTSM
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
CMS Awards Tempus With Advanced Diagnostic Laboratory Test (ADLT) Status for its xT CDx Test
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces Pricing of Initial Public Offering
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.